samedan logo
 
 
 
spacer
home > ebr > summer 2003 > how to include genetic analysis in clinical trials
PUBLICATIONS
European Biopharmaceutical Review

How to Include Genetic Analysis in Clinical Trials

The demand for genetic analysis in clinical trials is increasing. This is partly due to the growing realisation that understanding the genetic variation within a clinical trial population can improve the design, safety and outcome of the trial. A second major driver is the encouragement that the regulatory authorities, in particular the FDA, are giving to the inclusion of a pharmacogenomic element. For the pharmaceutical company or CRO wishing to incorporate a genetic analysis component there are now a number of service providers who have both the technical ability and appropriate quality systems to provide clinical trial grade genotyping.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Stephen Little, CEO of DxS Ltd

Dr Stephen Little is Chief Executive and Co-Founder of DxS Ltd, a UK biotech company providing pharmacogenomic services to the health care industry. Prior to forming DxS, he was a Board and Executive Team Member at AstraZeneca Diagnostics with overall responsibility for R&D within the business.

Dr Little has extensive experience in the development of nucleic acid-based diagnostic technology, products and services for human genetic analysis gained from over 20 years working in the biotechnology industry.

spacer
Dr Stephen Little
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

IBM Research and Arctoris Accelerate Closed Loop Drug Discovery with AI and Cloud

Oxford and Zurich 13 September 2021 Life Science Newswire Today, IBM Research and Arctoris announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery. IBM Research has developed RXN for Chemistry, an online platform leveraging state-of-the-art Natural Language Processing (NLP) architectures to automate synthetic chemistry.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement